Steven Seedhouse
Stock Analyst at Raymond James
(3.24)
# 930
Out of 4,874 analysts
172
Total ratings
43.11%
Success rate
2.21%
Average return
Main Sectors:
Stocks Rated by Steven Seedhouse
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Strong Buy | $73 → $77 | $50.13 | +53.60% | 19 | May 13, 2025 | |
| KRRO Korro Bio | Initiates: Overweight | $74 | $11.94 | +519.77% | 2 | Apr 29, 2025 | |
| WVE Wave Life Sciences | Initiates: Overweight | $10 | $6.85 | +45.99% | 3 | Apr 29, 2025 | |
| PHVS Pharvaris | Initiates: Overweight | $28 | $17.28 | +62.04% | 1 | Apr 29, 2025 | |
| ATXS Astria Therapeutics | Initiates: Overweight | $47 | $5.65 | +731.86% | 1 | Apr 29, 2025 | |
| IFRX InflaRx | Initiates: Overweight | $10 | $0.84 | +1,090.48% | 14 | Apr 29, 2025 | |
| BCRX BioCryst Pharmaceuticals | Initiates: Overweight | $20 | $9.74 | +105.34% | 1 | Apr 29, 2025 | |
| VKTX Viking Therapeutics | Initiates: Overweight | $104 | $27.09 | +283.91% | 19 | Apr 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Outperform | $90 → $22 | $1.56 | +1,310.26% | 2 | Dec 11, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $51 → $56 | $18.34 | +205.34% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $53 → $49 | $9.76 | +402.05% | 10 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $6 → $14 | $2.16 | +548.15% | 6 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $93 | $105.93 | -12.21% | 9 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $57 → $68 | $23.31 | +191.72% | 3 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $67 → $106 | $18.39 | +476.40% | 15 | Jan 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $12 → $15 | $3.63 | +313.22% | 2 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $27 → $56 | $10.42 | +437.43% | 4 | Jan 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $19 → $18 | $0.28 | +6,099.08% | 8 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $57 | $9.56 | +496.23% | 10 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $20 → $22 | $1.18 | +1,764.41% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $17 | $2.19 | +676.26% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $35 | $2.65 | +1,220.75% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $38 | $46.47 | -18.23% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Strong Buy | $30 → $71 | $29.90 | +137.46% | 4 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $15 → $5 | $1.36 | +267.65% | 5 | Dec 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $38 | $23.24 | +63.51% | 2 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $13.95 | - | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.81 | - | 5 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $285 → $270 | $18.00 | +1,400.00% | 1 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $127.31 | - | 2 | Apr 23, 2020 |
Mirum Pharmaceuticals
May 13, 2025
Maintains: Strong Buy
Price Target: $73 → $77
Current: $50.13
Upside: +53.60%
Korro Bio
Apr 29, 2025
Initiates: Overweight
Price Target: $74
Current: $11.94
Upside: +519.77%
Wave Life Sciences
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $6.85
Upside: +45.99%
Pharvaris
Apr 29, 2025
Initiates: Overweight
Price Target: $28
Current: $17.28
Upside: +62.04%
Astria Therapeutics
Apr 29, 2025
Initiates: Overweight
Price Target: $47
Current: $5.65
Upside: +731.86%
InflaRx
Apr 29, 2025
Initiates: Overweight
Price Target: $10
Current: $0.84
Upside: +1,090.48%
BioCryst Pharmaceuticals
Apr 29, 2025
Initiates: Overweight
Price Target: $20
Current: $9.74
Upside: +105.34%
Viking Therapeutics
Apr 28, 2025
Initiates: Overweight
Price Target: $104
Current: $27.09
Upside: +283.91%
Q32 Bio
Dec 11, 2024
Downgrades: Outperform
Price Target: $90 → $22
Current: $1.56
Upside: +1,310.26%
Dianthus Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $51 → $56
Current: $18.34
Upside: +205.34%
Nov 8, 2024
Maintains: Strong Buy
Price Target: $53 → $49
Current: $9.76
Upside: +402.05%
Oct 29, 2024
Upgrades: Strong Buy
Price Target: $6 → $14
Current: $2.16
Upside: +548.15%
Jul 8, 2024
Upgrades: Outperform
Price Target: $93
Current: $105.93
Upside: -12.21%
May 10, 2024
Maintains: Strong Buy
Price Target: $57 → $68
Current: $23.31
Upside: +191.72%
Jan 11, 2024
Maintains: Strong Buy
Price Target: $67 → $106
Current: $18.39
Upside: +476.40%
Jan 9, 2024
Maintains: Strong Buy
Price Target: $12 → $15
Current: $3.63
Upside: +313.22%
Jan 4, 2024
Maintains: Strong Buy
Price Target: $27 → $56
Current: $10.42
Upside: +437.43%
Nov 14, 2023
Maintains: Outperform
Price Target: $19 → $18
Current: $0.28
Upside: +6,099.08%
Nov 10, 2023
Maintains: Outperform
Price Target: $78 → $57
Current: $9.56
Upside: +496.23%
Aug 15, 2023
Maintains: Strong Buy
Price Target: $20 → $22
Current: $1.18
Upside: +1,764.41%
Jun 13, 2023
Upgrades: Outperform
Price Target: $17
Current: $2.19
Upside: +676.26%
May 5, 2023
Maintains: Outperform
Price Target: $33 → $35
Current: $2.65
Upside: +1,220.75%
May 5, 2023
Upgrades: Outperform
Price Target: $38
Current: $46.47
Upside: -18.23%
Dec 15, 2022
Maintains: Strong Buy
Price Target: $30 → $71
Current: $29.90
Upside: +137.46%
Dec 7, 2022
Maintains: Outperform
Price Target: $15 → $5
Current: $1.36
Upside: +267.65%
Nov 9, 2022
Maintains: Outperform
Price Target: $30 → $38
Current: $23.24
Upside: +63.51%
Aug 10, 2022
Downgrades: Underperform
Price Target: n/a
Current: $13.95
Upside: -
May 18, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.81
Upside: -
Aug 6, 2021
Maintains: Outperform
Price Target: $285 → $270
Current: $18.00
Upside: +1,400.00%
Apr 23, 2020
Downgrades: Sell
Price Target: n/a
Current: $127.31
Upside: -